



(51) International Patent Classification:

A61K 39/00 (2006.01) *G16B 20/20* (2019.01)
C12Q 1/6869 (2018.01)

(21) International Application Number:

PCT/EP2022/058793

(22) International Filing Date:

01 April 2022 (01.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2104715.4 01 April 2021 (01.04.2021) GB

(71) Applicant: **ACHILLES THERAPEUTICS UK LIMITED** [GB/GB]; 245 Hammersmith Road, London, Greater London W6 8PW (GB).(72) Inventors: **ROTH, Andrew**; c/o Oxford University Innovation Limited, Buxton Court, 3 West Way, Oxford, Oxfordshire OX2 0JB (GB). **SALM-HORSTMAR, Maximilian Prinz Zu**; c/o Achilles Therapeutics UK Ltd, 245 Hammersmith Road, London, Greater London W7 8PW (GB). **CHAN, Fong Chun**; c/o Achilles Therapeutics UK Ltd, 245 Hammersmith Road, London, Greater London W7 8PW (GB).(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: IDENTIFICATION OF CLONAL NEOANTIGENS AND USES THEREOF




Fig. 1

(57) Abstract: A method of determining whether a tumour-specific mutation is likely to be clonal in a subject is provided. The method comprises providing sequence data from one or more samples from the subject comprising tumour genetic material, the sequence data comprising for each of the one or more samples, and determining the likelihood that the tumour-specific mutation is clonal as a posterior probability depending on: a prior probability of the mutation being clonal, and the probabilities of observing the sequence data if the tumour-specific mutation is (i) clonal and (ii) non-clonal, in view of a tumour fraction for each of the one or more samples and one or more candidate joint genotypes. Related methods, systems and products are also described.

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*